Posted by linkadge on July 15, 2006, at 0:41:57
In reply to Re: couldn't have said it better myself, posted by SLS on July 14, 2006, at 22:55:22
The claim made by the first article I posted was this:
The two lead STAR*D investigators Dr. A. John Rush and Dr. Madhukar H. Trivedi receive consulting fees from or served on the advisory boards for Forest Pharmaceuticals (Celexa), Wyeth-Ayerst Laboratories (Effexor), and Bristol-Myers Squibb (Buspar); while Dr. Rush has such a relationship with GlaxoSmithKline (Wellbutrin) and Dr. Tiveldi has such a relationship with Pfizer (Zoloft); and Dr. Rush has an equity interest in Pfizer. Both have received speaker fees from Forest Pharmaceuticals; Dr. Rush has received speaker fees from GlaxoSmithKline; and Dr. Trivedi has received speaker fees from Wyeth-Ayerst Laboratories and Bristol-Myers Squibb.
-----------
That information may be incorrect, but if it is correct, it would seem to be reason enough to believe that data could be squewed in any possable direction.
Statistical analysis is not an exact science, and there are likely hundreds of ways to collect data in ones own favor. That is why I would think it necessary to produce a study in which those in charge don't give a rats behind if the drug fails.
Linkadge
poster:linkadge
thread:662854
URL: http://www.dr-bob.org/babble/20060709/msgs/667204.html